Fasting-mimicking diet in type 2 diabetes reduces myocardial triglyceride content: A 12-month randomised controlled trial
A 12-month randomized trial in 100 people with type 2 diabetes, measuring fat inside the heart muscle.
Nutr Metab Cardiovasc Dis, 2025. Roos PR, et al.
Funding and competing interests (as published with the paper): FundingOpen access funding provided by SCELC, Statewide California Electronic Library Consortium. This work was supported by L-Nutra, Inc. L-Nutra, Inc. did not participate in the conduct of the study, data collection, or analysis. Competing interestsThe authors declare no competing interests.
- Study type
- Human clinical trial (randomized, n=100)
- Journal
- Nutr Metab Cardiovasc Dis
- Published
- 2025
- Authors
- Roos PR, et al.
- DOI
- 10.1016/j.numecd.2025.103860
- PubMed ID
- 39934050
Summary
One hundred patients with type 2 diabetes who used metformin as their only glucose-lowering drug, or no medication, were randomly assigned to a Fasting Mimicking Diet (FMD) programme for five consecutive days a month alongside usual care, or to usual care only. Both groups were examined at baseline, 6 months and 12 months, including single voxel cardiac magnetic resonance spectroscopy to measure myocardial triglyceride content. Complete data at both baseline and twelve months were available for 13 participants in the diet group and 13 in the control group.
The authors reported a reduction in myocardial triglyceride content over twelve months in the diet group and no significant change in the control group, and that the difference between the groups was statistically significant. They described this as indicating a favourable effect on cardiac metabolism.
Although one hundred patients were randomized, the heart measurement reported here was complete for only thirteen participants in each group, which is a very small basis for the comparison. The outcome is the fat content of heart muscle measured by spectroscopy, not a cardiovascular event. Participants were patients with type 2 diabetes, not a general wellness population. L-Nutra, Prolon's parent company, supported this work.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.